Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2019 Q2- Text added to 2019 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
acetonide, Aly, Aplenzin, augment, Bahaa, Benzamycin, Biomedical, BIRL, Brilliant, chargeback, CIC, Clearside, cohesive, complement, Connecticut, counterparty, dealing, decided, dispersive, division, edema, Equivalence, EU, faith, fiduciary, fluctuation, Fraxel, genericized, hedge, hedged, hedging, hereof, Humana, ineffective, interference, interlocutory, Librax, licensor, metformin, Microinjector, MoviPrep, NaN, Northern, notional, nullity, payer, Pearson, Philadelphia, Praecipe, preliminarily, reestablishing, Sandoz, SCS, Shabbouei, Sigma, SpA, spot, suprachoroidal, trend, triamcinolone, Uniform, unjust, VASERlipo, waste, Xipere
Valuein 2019 Q2 filing- Value in 2019 Q3 filing
Original filings
Filing view